High-density lipoprotein cholesterol, obesity, and mammographic density in korean women: The healthy twin study

Journal of Epidemiology

Volumn 21, Issue 1, 2011, Pages 52-60

  Sung, Joohon ^a   Song, Yun Mi ^b   Stone, Jennifer ^c   Lee, Kayoung ^d   Kim, Sun Young ^e  

^a Seoul National University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Inje University College of Medicine   (South Korea)

^e School of Medicine   (South Korea)

Author keywords

Breast cancer; High density lipoprotein cholesterol; Mammography; Obesity

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD; BODY MASS; BREAST; BREAST TUMOR; FEMALE; HISTOLOGY; HUMAN; KOREA; MAMMOGRAPHY; MIDDLE AGED; OBESITY; RISK FACTOR; TWINS;

ADULT; BODY MASS INDEX; BREAST; BREAST NEOPLASMS; CHOLESTEROL, HDL; FEMALE; HUMANS; KOREA; MAMMOGRAPHY; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 78651520978     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20100078     Document Type: Article

References (54)

1. Ferraroni M, Gerber M, Decarli A, Richardson S, Marubini E, Crastes de Paulet P, et al. HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol. 1993;22:772-80.
2. Furberg AS, Veierø MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96:1152-60.
3. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev. 2005;14:33-40.
4. Chen JK, LaBrake-Farmer S, McClure DB. Purified HDLapolipoproteins, A-I and C-III, substitute for HDL in promoting the growth of SV40-transformed REF52 cells in serum-free medium. J Cell Physiol. 1986;128:413-20.
5. Gospodarowicz D, Lui GM, Gonzalez R. High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium. Cancer Res. 1982;42:3704-13.
6. Cowan LD, O'Connell DL, Criqui MH, Barrett-Connor E, Bush TL, Wallace RB. Cancer mortality and lipid and lipoprotein levels. Lipid Research Clinics Program Mortality Follow-up Study. Am J Epidemiol. 1990;131:468-82.
7. Boyd NF, Connelly P, Lynch H, Knaus M, Michal S, Fili M, et al. Plasma lipids, lipoproteins, and familial breast cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:117-22.
8. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine. 2005;26:19-24.
9. Høyer AP, Engholm G. Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control. 1992;3:403-8.
10. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem. 2001;34:71-6.
11. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem. 2005;268:19-24.
12. Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha EH, et al. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Cancer Epidemiol Biomarkers Prev. 2009;18:508-15.
13. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control. 1994;5:501-9.
14. Byrne C, Schairer C, Brinton LA, Wolfe J, Parekh N, Salane M, et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control. 2001;12:103-10.
15. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:1133-44.
16. Heng D, Gao F, Jong R, Fishell E, Yaffe M, Martin L, et al. Risk factors for breast cancer associated with mammographic features in Singaporean chinese women. Cancer Epidemiol Biomarkers Prev. 2004;13:1751-8.
17. Nagao Y, Kawaguchi Y, Sugiyama Y, Saji S, Kashiki Y. Relationship between mammographic density and the risk of breast cancer in Japanese women: a case-control study. Breast Cancer. 2003;10:228-33.
18. Grove JS, Goodman MJ, Gilbert FI Jr, Mi MP. Factors associated with mammographic pattern. Br J Radiol. 1985;58:21-5.
19. Brisson J, Sadowsky NL, Twaddle JA, Morrison AS, Cole P, Merletti F. The relation of mammographic features of the breast to breast cancer risk factors. Am J Epidemiol. 1982;115:438-43.
20. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95:30-7.
21. Gorbach SL, Schaefer EJ, Woods M, Longcope C, Dwyer JT, Goldin BR, et al. Plasma lipoprotein cholesterol and endogenous sex hormones in healthy young women. Metabolism. 1989;38:1077-81.
22. Boyd NF, Connelly P, Byng J, Yaffe M, Draper H, Little L, et al. Plasma lipids, lipoproteins, and mammographic densities. Cancer Epidemiol Biomarkers Prev. 1995;4:727-33.
23. Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, et al. Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:1411-7.
24. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev. 2001;10:15-32.
25. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas. 2001;38:103-13.
26. Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, et al. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat. 2008;108:57-67.
27. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med. 1999;130:262-9.
28. Walker K, Fletcher O, Johnson N, Coupland B, McCormack VA, Folkerd E, et al. Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res. 2009;69:6490-9.
29. Kesteloot H, Huang DX, Yang XS, Claes J, Rosseneu M, Geboers J, et al. Serum lipids in the People's Republic of China. Comparison of Western and Eastern populations. Arteriosclerosis. 1985;5:427-33.
30. Kesteloot H, Lee CS, Park HM, Kegels C, Geboers J, Claes JH, et al. A comparative study of serum lipids between Belgium and Korea. Circulation. 1982;65:795-9.
31. Habel LA, Capra AM, Oestreicher N, Greendale GA, Cauley JA, Bromberger J, et al. Mammographic density in a multiethnic cohort. Menopause. 2007;14:891-9.
32. McCormack VA, Perry N, Vinnicombe SJ, dos Santos Silva I. Ethnic variations in mammographic density: a British multiethnic longitudinal study. Am J Epidemiol. 2008;168:412-21.
33. Tominaga S, Kuroishi T. Epidemiology and Prevention of Breast Cancer in the 21st Century. Breast Cancer. 1999;6:283-8.
34. Yoo KY, Kim Y, Park SK, Kang D. Lifestyle, genetic susceptibility and future trends of breast cancer in Korea. Asian Pac J Cancer Prev. 2006;7:679-82.
35. Sung J, Cho SI, Lee K, Ha M, Choi EY, Choi JS, et al. Healthy Twin: a twin-family study of Korea-protocols and current status. Twin Res Hum Genet. 2006;9:844-8.
36. Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics. 1998;18:1587-98.
37. The World Health Organization Western Pacific Region, The International Association for the Study of Obesity, The International Obesity Task Force. The Asia-Pacific Perspective: redefining obesity and its treatment, Sidney: Health Communications Australia Pty Limited; 2000.
38. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198-211.
39. Berkowitz JE, Gatewood OM, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology. 1990;174:199-201.
40. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 1992;41:1193-8.
41. Harvey JA, Santen RJ, Petroni GR, Bovbjerg VE, Smolkin ME, Sheriff FS, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause. 2008;15:67-73.
42. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst. 2005;97:1366-76.
43. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350:1047-59.
44. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942-4.
45. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
46. Boyd NF, McGuire V, Fishell E, Kuriov V, Lockwood G, Tritchler D. Plasma lipids in premenopausal women with mammographic dysplasia. Br J Cancer. 1989;59:766-71.
47. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641-6.
48. Stone J, Warren RM, Pinney E, Warwick J, Cuzick J. Determinants of percentage and area measures of mammographic density. Am J Epidemiol. 2009;170:1571-8.
49. Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL. The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer. 1998;78:1233-8.
50. Sala E, Warren R, McCann J, Duffy S, Luben R, Day N. Highrisk mammographic parenchymal patterns and anthropometric measures: a case-control study. Br J Cancer. 1999;81:1257-61.
51. Ha M, Sung J, Song YM. Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women. Cancer Causes Control. 2009;20:1055-60.
52. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6:798-808.
53. Barnett JB, Woods MN, Lamon-Fava S, Schaefer EJ, McNamara JR, Spiegelman D, et al. Plasma lipid and lipoprotein levels during the follicular and luteal phases of the menstrual cycle. J Clin Endocrinol Metab. 2004;89:776-82.
54. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev. 2001;10:141-2.